glp 1 sex drive GLP-1s and Libido: What the Research Shows SMSNA - What Effects do

The response to treatment should be assessed ideally at the end of six months

The skin is the body's largest organ, yet it's often one of the most overlooked areas of research

Prescription NAD+ therapy takes a different approachsupporting cellular energy production directly

Many patients reported meaningful changes in how they felt about their sexual relationships and their own sexual identity, underscoring the importance of addressing both desire and distress together

Treatment of diseases associated with impaired appetite regulation e.g

It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans ( APOC3 - the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk ( Structure and Regulation of APOC-III APOC3 is expressed in hepatocytes and, to a lesser extent in enterocytes ( 0 , monosialylated apoC-III 1 and disialylated apoC-III 2 ( The transcription rate of APOC3 is decreased by insulin (Figure 1) ( APOC3 via hepatic nuclear factor-4 ( HNF4) and carbohydrate-responsive element binding protein (ChREBP) ( APOC3 expression is therefore upregulated in states of insulin resistance (characterized by insulin resistance and hyperglycemia), and recent results demonstrate that glycaemic control is a major determinant of apoC-III secretion rate in vivo (as measured by stable isotope technology) and thus plasma apoC-III levels ( Figure 1 APOC3 antisense oligonucleotides (ASO) reduces hepatic APOC3 expression ( The regulation of hepatic apoC-III expression is now reasonably well-understood, but much less is known of the control of apoC-III synthesis and secretion in the intestine